Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Overcoming Obstacles in Cancer Nanomedicine Delivery using a Versatile In Situ Ultrasound-Triggered Microbubble-to-Nanoparticle Conversion

FY 2018-19

Summary
Difficult-to-treat solid tumours have long been a problem for the cancer research community. While modern advances in nanomedicine have created smart drugs that are designed to specifically target different cancers, the improvement they provide is limited by the amount of drug that can infiltrate the complex tumour environment relative to normal, healthy tissue. The development of a delivery system that could load drugs and be selectively triggered to release them into the tumour would revolutionize drug design for some of the deadliest cancers. In 2015, researchers discovered that specially designed contrast agents called microbubbles could be converted into stable nanostructures using a particular type of ultrasound. While microbubbles themselves must remain in the blood vessels, these smaller structures have the potential to leave the circulation and enter their surrounding environment. This opens up the possibility of loading a microbubble with therapeutic nanoparticles and initiating the conversion at a tumour boundary, enhancing local delivery at the tumour site. Because the delivery platform would not depend on the drug itself, it could be used to deliver all types of nanoagents in a versatile and consistent manner. This would open new doors for those designing cancer drugs, allowing for researchers to use more specialized nanomedicines at lower doses and with fewer systemic side-effects. This tool and its accompanying shift in the mindset of drug development is necessary in order to produce the next wave of therapies that will help us fight the most lethal cancers.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
397975
Name
Dhaliwal Alexander K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Overcoming Obstacles in Cancer Nanomedicine Delivery using a Versatile In Situ Ultrasound-Triggered Microbubble-to-Nanoparticle Conversion
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cancer; Drug-Delivery; Microbubbles; Nanomedicine; Optical Imaging; Ultrasound
Abstract
Difficult-to-treat solid tumours have long been a problem for the cancer research community. While modern advances in nanomedicine have created smart drugs that are designed to specifically target different cancers, the improvement they provide is limited by the amount of drug that can infiltrate the complex tumour environment relative to normal, healthy tissue. The development of a delivery system that could load drugs and be selectively triggered to release them into the tumour would revolutionize drug design for some of the deadliest cancers. In 2015, researchers discovered that specially designed contrast agents called microbubbles could be converted into stable nanostructures using a particular type of ultrasound. While microbubbles themselves must remain in the blood vessels, these smaller structures have the potential to leave the circulation and enter their surrounding environment. This opens up the possibility of loading a microbubble with therapeutic nanoparticles and initiating the conversion at a tumour boundary, enhancing local delivery at the tumour site. Because the delivery platform would not depend on the drug itself, it could be used to deliver all types of nanoagents in a versatile and consistent manner. This would open new doors for those designing cancer drugs, allowing for researchers to use more specialized nanomedicines at lower doses and with fewer systemic side-effects. This tool and its accompanying shift in the mindset of drug development is necessary in order to produce the next wave of therapies that will help us fight the most lethal cancers.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dhaliwal, Alexander K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2018-19) | Canada Spends